# US 2024/0123080 A1 · Cytotoxic compounds and conjugates thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0123080 A1
- Document ID: US20240123080A1
- Status: Published application
- Kind: A1
- Application number: 18/448,863
- Filed: 2023-08-11
- Published: 2024-04-18
- Earliest claimed: 2022-08-12
- Assignees: Seagen Inc.
- Applicants: Seagen Inc.
- Inventors: Philip MOQUIST; Svetlana DORONINA; Nicole DUNCAN; Gabriele BLAHNIK-FAGAN; Sharsti SANDALL
- Web page: https://patentgrep.com/patent/US20240123080A1

## CPC

- A61K 47/68031: {the drug being an auristatin}
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07K 5/06052: {Val-amino acid}
- C07K 5/06069: {Ser-amino acid}
- C07K 5/101: {the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Hydrophilic auristatin compounds are described, including Drug-Linker compounds, Ligand-Drug Conjugate compounds, methods of use, and preparations thereof.

## Claims

### Claim 1

A compound of Formula (I):
or a salt thereof, wherein
Xb is —NR1R2; and Xa is
or
Xa and Xb are taken together with the carbon atom to which they are attached to form
wherein the asterisk denotes the carbon atom of Formula (I) that bears the Xa and Xb groups;
R1, R2, R3, R4, Ra, Rb, R5, and R10 are each independently H or C1-C4 alkyl;
X is H, OH, —C(O)NRaRb, —S(O)2Ra, —S(O)—Ra —S(O)2NRaRb, —NHS(O)2Ra, or —NHC(O)Ra;
R6 is C1-C4 alkyl optionally substituted with OH;
R7 is H, C1-C4 alkyl optionally substituted with one or two OH moieties, or 5-6 membered heteroaryl;
E is phenyl or 5-6 membered heteroaryl;
R8, R9, and R11 are each independently H or OH;
n is 0, 1, 2, or 3;
m is 1, 2, 3, or 4; and
q is 0 or 1,
wherein when X is H, at least two of R7, R8, R9, and R11 comprise an OH moiety.

### Claim 2

A compound of Formula (II):
or a salt thereof, wherein
R1, R3, and R4 are independently H or C1-C4 alkyl;
R6 is C1-C4 alkyl optionally substituted with OH;
R7 is H, C1-C4 alkyl optionally substituted with one or two OH moieties, or 5-6 membered heteroaryl;
E is phenyl or 5-6 membered heteroaryl;
R8, R9, and R11 are each independently H or OH;
n is 0, 1, or 2; and
q is 0 or 1.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, wherein q is 0.

### Claim 4 (depends on 1, 2)

The compound of claim 1 or 2, wherein q is 1.

### Claim 5 (depends on 1)

The compound of claim 1, or a salt thereof, wherein
X is OH.

### Claim 6 (depends on 1)

The compound of claim 1, or a salt thereof, wherein
X is —C(O)NRaRb, —S(O)2Ra, —S(O)—Ra —S(O)2NRaRb, —NHS(O)2Ra, or —NHC(O)Ra.

### Claim 7 (depends on 1, 3, 4, 5, 6)

The compound of any one of claims 1 or 3-6, or a salt thereof, wherein
Xb is —NR1R2; and
Xa is

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, or a salt thereof, wherein R3 is H.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, or a salt thereof, wherein R4 is H.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound of any one of claims 1-9, or a salt thereof, wherein n is 0 or 1.

### Claim 11 (depends on 1, 3, 4, 5, 6)

The compound of any one of claims 1 or 3-6, or a salt thereof, wherein
Xa and Xb are taken together with the carbon atom to which they are attached to form
wherein the asterisk denotes the carbon atom of Formula (I) that bears the Xa and Xb groups.

### Claim 12 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1 or 3-11, wherein m is 1 or 2.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10, or a salt thereof, wherein R1 is H.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10, or a salt thereof, wherein R1 is C1-C4 alkyl.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14)

The compound of any one of claims 1-10 or 14, or a salt thereof, wherein R1 is methyl.

### Claim 16 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1, 3-10, or 13-15, or a salt thereof, wherein R2 is methyl.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-16, or a salt thereof, wherein R10 is H.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-16, or a salt thereof, wherein R10 is methyl.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of claims 1-18, or a salt thereof, wherein R6 is unsubstituted C1-C4 alkyl.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1-19, or a salt thereof, wherein R6 is isopropyl.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of claims 1-18, or a salt thereof, wherein R6 is C1-C4 alkyl substituted with OH.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any one of claims 1-21, or a salt thereof, wherein R7 C1-C4 alkyl substituted with OH.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The compound of any one of claims 1-22, or a salt thereof, wherein R7 is —CH2OH.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any one of claims 1-21, or a salt thereof, wherein R7 is H.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any one of claims 1-21, or a salt thereof, wherein R7 is unsubstituted C1-C4 alkyl.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 25)

The compound of any one of claims 1-21 or 25, or a salt thereof, wherein R7 is methyl.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any one of claims 1-21, or a salt thereof, wherein R7 is 5-6 membered heteroaryl.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The compound of any one of claims 1-27, or a salt thereof, wherein R8 is H.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 1-28, or a salt thereof, wherein R8 is OH.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound of any one of claims 1-29, or a salt thereof, wherein E is phenyl.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The compound of any one of claims 1-30, or a salt thereof, wherein E-R9 is
and
the wavy line indicates the point of attachment of E to the rest of the compound.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound of any one of claims 1-29, or a salt thereof, wherein E is 5-6 membered heteroaryl.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The compound of any one of claims 1-32, or a salt thereof, wherein R9 is H.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The compound of any one of claims 1-33, or a salt thereof, wherein R9 is OH.

### Claim 35 (depends on 1)

The compound of claim 1, or a salt thereof, wherein
Xa is
Xb is —NR1R2;
R1 is H or methyl;
R2 is methyl;
X is OH;
R3 and R4 are H;
R6 is isopropyl;
R7 is —CH2OH;
R8 is H;
E is phenyl; and
R9 is H.

### Claim 36 (depends on 1)

The compound of claim 1, wherein the compound is
or a salt thereof.

### Claim 37

A Drug-Linker compound of the following formula:
Q-D,
or a salt thereof, wherein
Q is a Linker Unit selected from the group consisting of:
(i) Z′-A-RL-,
(ii) Z′-A-RL-Y—,
(iii) Z′-A-S*—RL-,
(iv) Z′-A-S*—RL-Y—,
(v) Z′-A-B(S*)—RL-,
(vi) Z′-A-B(S*)—RL-Y—,
(vii) Z′-A-,
(viii) Z′-A-S*—W—,
(ix) Z′-A-B(S*)—W—,
(x) Z′-A-S*—W-RL-, and
(xi) Z′-A-B(S*)—W-RL-;
Z′ is a Stretcher Unit precursor;
A is a bond or a Connector Unit;
B is a Parallel Connector Unit;
S* is a Partitioning Agent;
RL is a Releasable Linker;
W is an Amino Acid Unit;
Y is a Spacer Unit; and
D is a Drug Unit of Formula (I′):
wherein
Xb is —NR2—# or —N+R1R5—#, wherein the # denotes the point of attachment to Q, and Xa is
or
Xa and Xb are taken together with the carbon atom to which they are attached to form
wherein the asterisk denotes the carbon atom of Formula (I) that bears the Xa and Xb groups, and the # denotes the point of attachment to Q;
R1 and R5 are independently C1-C4 alkyl;
X is H, OH, —C(O)NRaRb, —S(O)2Ra, —S(O)—Ra —S(O)2NRaRb, —NHS(O)2Ra, or —NHC(O)Ra;
R2, R3, R4, R10, Ra, and Rb are each independently H or C1-C4 alkyl;
R6 is C1-C4 alkyl optionally substituted with OH;
R7 is H, C1-C4 alkyl optionally substituted with one or two OH moieties, or 5-6 membered heteroaryl;
E is phenyl or 5-6 membered heteroaryl;
R8, R9, and R11 are each independently H or OH;
n is 0, 1, 2, or 3;
m is 1, 2, 3, or 4;
q is 0 or 1; and
wherein when X is H, at least two of R7, R8, R9, and R11 comprise an OH moiety.

### Claim 38 (depends on 37)

The Drug-Linker compound of claim 37, or a salt thereof, wherein the Linker Unit Q is of formula (i), (ii), (iii), (iv), (x), or (xi).

### Claim 39 (depends on 37)

The Drug-Linker compound of claim 37, or a salt thereof, wherein the Linker Unit Q is of formula (v), (vi), (ix), or (xi).

### Claim 40 (depends on 37)

The Drug-Linker compound of claim 37, or a salt thereof, wherein the Linker Unit Q is of formula (viii), (ix), (x), or (xi).

### Claim 41 (depends on 37, 38, 39, 40)

The Drug-Linker compound of any one of claims 37-40, or a salt thereof, wherein the Stretcher Unit Z′ is
wherein
R17 is —CH2CH2(OCH2CH2)k—, —C1-C10 alkylene-, C1-C10 heteroalkylene-, —C3-C8 carbocyclo-, —O—(C1-C8 alkylene)-, -arylene-, —C1-C10 alkylene-arylene-, -arylene-C1-C10 alkylene-, —C1-C10 alkylene-(C3-C8 carbocyclo)-, —(C3-C8 carbocyclo)-C1-C10 alkylene-, —C3-C8 heterocyclo-, —C1-C10 alkylene-(C3-C8 heterocyclo)-, —(C3-C8 heterocyclo)-C1-C10 alkylene-, —C1-C10 alkylene-C(═O)—, C1-C10 heteroalkylene-C(═O)—, —C3-C8 carbocyclo-C(═O)—, —O—(C1-C8 alkylene)-C(═O)—, -arylene-C(═O)—, —C1-C10 alkylene-arylene-C(═O)—, -arylene-C1-C10 alkylene-C(═O)—, —C1-C10 alkylene-(C3-C8 carbocyclo)-C(═O)—, —(C3-C8 carbocyclo)-C1-C10 alkylene-C(═O)—, —C3-C8 heterocyclo-C(═O)—, —C1-C10 alkylene-(C3-C8 heterocyclo)-C(═O)—, —(C3-C8 heterocyclo)-C1-C10 alkylene-C(═O)—, —C1-C10 alkylene-NH—, C1-C10 heteroalkylene-NH—, —C3-C8 carbocyclo-NH—, —O—(C1-C8 alkylene)-NH—, -arylene-NH—, —C1-C10 alkylene-arylene-NH—, -arylene-C1-C10 alkylene-NH—, —C1-C10 alkylene-(C3-C8 carbocyclo)-NH—, —(C3-C8 carbocyclo)-C1-C10 alkylene-NH—, —C3-C8 heterocyclo-NH—, —C1-C10 alkylene-(C3-C8 heterocyclo)-NH—, —(C3-C8 heterocyclo)-C1-C10 alkylene-NH—, —C1-C10 alkylene-S—, C1-C10 heteroalkylene-S—, —C3-C8 carbocyclo-S—, —O—(C1-C8 alkylene)-S—, -arylene-S—, —C1-C10 alkylene-arylene-S—, -arylene-C1-C10 alkylene-S—, —C1-C10 alkylene-(C3-C8 carbocyclo)-S—, —(C3-C8 carbocyclo)-C1-C10 alkylene-S—, —C3-C8 heterocyclo-S—, —C1-C10 alkylene-(C3-C8 heterocyclo)-S—, or —(C3-C8 heterocyclo)-C1-C10 alkylene-S—;
subscript k is an integer ranging from 1 to 36;
R17 is optionally substituted by a Basic Unit (BU) such as an aminoalkyl moiety, e.g. —(CH2)xNH2, —(CH2)xNHRa, and —(CH2)xNRa2, wherein x is an integer of from 1-4 and each Ra is independently selected from the group consisting of C1-6 alkyl and C1-6 haloalkyl, or two Ra groups are combined with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl or piperidinyl group; and
the wavy line indicates the point of covalent attachment to the rest of the Drug-Linker compound.

### Claim 42 (depends on 37, 38, 39, 40, 41)

The Drug-Linker of any one of claims 37-41, or a salt thereof, wherein the Stretcher Unit Z′ is
wherein the wavy lines indicate the point of covalent attachment to the rest of the Drug-Linker compound.

### Claim 43 (depends on 37, 38, 39, 40, 41, 42)

The Drug-Linker compound of any one of claims 37-42, or a salt thereof, wherein the Connector Unit A is
wherein
each R100 is independently selected from hydrogen or —C1-C3 alkyl;
R111 is independently selected from the group consisting of hydrogen, p-hydroxybenzyl, methyl, isopropyl, isobutyl, sec-butyl, —CH2OH, —CH(OH)CH3, —CH2CH2SCH3, —CH2CONH2, —CH2COOH, —CH2CH2CONH2, —CH2CH2COOH, —(CH2)3NHC(═NH)NH2, —(CH2)3NH2, —(CH2)3NHCOCH3, —(CH2)3NHCHO, —(CH2)4NHC(═NH)NH2, —(CH2)4NH2, —(CH2)4NHCOCH3, —(CH2)4NHCHO, —(CH2)3NHCONH2, —(CH2)4NHCONH2, —CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3-pyridylmethyl-, 4-pyridylmethyl-,
each subscript c is an independently selected integer from 1 to 10; and
the wavy lines indicate attachment of the Connector Unit to the rest of the Drug-Linker compound.

### Claim 44 (depends on 37, 38, 39, 40, 41, 42, 43)

The Drug-Linker compound of any one of claims 37-43, or a salt thereof, wherein the Connector Unit A is
c is an integer ranging from 1 to 6; and
the wavy lines indicate the site of attachment to the rest of the Drug-Linker compound or salt thereof.

### Claim 45 (depends on 37, 38, 39, 40, 41, 42)

The Drug-Linker compound of any one of claims 37-42, or a salt thereof, wherein A is a bond.

### Claim 46 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45)

The Drug-Linker compound of claims 37-45, or a salt thereof, wherein B is
each AA is independently a proteinogenic or non-proteinogenic amino acid; and
the wavy lines indicate points of attachment to the rest of the Drug-Linker compound or salt thereof.

### Claim 47 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The Drug-Linker compound of any one of claims 37-46, or a salt thereof, wherein B is an amino acid.

### Claim 48 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The Drug-Linker compound of any one of claims 37-47, or a salt thereof, wherein B is
the wavy line indicates the point of attachment to the Partitioning Agent S*; and
the asterisks indicate points of attachment to the rest of the Drug-Linker structure.

### Claim 49 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The Drug-Linker compound of any one of claims 37-48, or a salt thereof, wherein the Partitioning Agent S* is a polyethylene glycol (PEG) unit, cyclodextrin unit, polyamide, hydrophilic peptide, polysaccharide, or dendrimer.

### Claim 50 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The Drug-Linker compound of any one of claims 37-49, or a salt thereof, wherein the Partitioning Agent S* is a PEG Unit comprising from 4 to 72 (CH2CH2O) subunits.

### Claim 51 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The Drug Linker of any one of claims 37-50, or a salt thereof, wherein the PEG Unit is
b is selected from the group consisting of 4 to 36; and
the wavy lines indicate the site of attachment to the rest of the Drug-Linker compound or salt thereof.

### Claim 52 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The Drug-Linker compound of any one of claims 37-51, or a salt thereof, wherein the Releasable Linker RL is
-(AA)1-12-; and
each AA is independently a proteinogenic or non-proteinogenic amino acid.

### Claim 53 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The Drug-Linker compound of any one of claims 37-52, or a salt thereof, wherein the Releasable Linker RL is
-AA1-AA2- or -AA1-AA2-AA3-, wherein AA1 is attached to the Stretcher Unit Z′ or the Connector Unit A.

### Claim 54 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The Drug-Linker compound of any one of claims 37-53, or a salt thereof, wherein the Releasable Linker RL is
and
the wavy line adjacent to the —NH— group indicates attachment to the Stretcher Unit Z′ or the Connector Unit A and the wavy line adjacent to the —C(═O)— group indicates attachment to the Spacer Unit Y or the Drug Unit D.

### Claim 55 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The Drug-Linker compound of any one of claims 37-54, or a salt thereof, wherein the Releasable Linker RL is a glycoside.

### Claim 56 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The Drug-Linker compound of any one of claims 37-55, or a salt thereof, wherein the Releasable Linker RL is
wherein
Su is a hexose form a monosaccharide;
O′ represents the oxygen atom of a glycosidic bond that is capable of cleavage by a glycosidase;
the wavy line marked with a single asterisk (*) indicates the site of covalent attachment to D; and
the wavy line marked with a double asterisk (**) indicates the site of covalent attachment to the remainder of Q.

### Claim 57 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The Drug-Linker compound of any one of claims 37-56, or a salt thereof, wherein the Releasable Linker RL is
the wavy line marked with a single asterisk (*) indicates the site of covalent attachment to D; and
the wavy line marked with a double asterisk (**) indicates the site of covalent attachment to the remainder of Q.

### Claim 58 (depends on 37, 38, 39, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The Drug-Linker compound of any one of claims 37-39 or 41-57, or a salt thereof, wherein the Spacer Unit Y is
wherein EWG is an electron-withdrawing group; and
the wavy lines indicate the site of attachment to the rest of the Drug-Linker compound or salt thereof.

### Claim 59 (depends on 37, 38, 39, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The Drug-Linker compound of any one of claims 37-39 or 41-58, or a salt thereof, wherein the Spacer Unit Y is
and
the wavy lines indicate the site of attachment to the rest of the Drug-Linker compound or salt thereof.

### Claim 60 (depends on 37, 41, 42, 45, 46, 47, 48, 52, 53, 54)

The Drug-Linker compound of any one of claims 37, 41-42, 45-48, 52-54, or 58-59, or a salt thereof, wherein
Z′ is
R17 is C1-C10 alkylene;
A is a bond;
RL is -AA1-AA2-;
AA1 and AA2 are each independently a proteinogenic amino acid;
Y is
and
the wavy lines indicate the site of attachment to the rest of the Drug-Linker compound or salt thereof.

### Claim 61 (depends on 37, 41, 42, 45, 46, 47, 48, 52, 53, 54)

The Drug-Linker compound of any one of claims 37, 41-42, 45-48, 52-54, or 58-60, or a salt thereof, wherein
Z′ is
A is a bond;
RL is
Y is

### Claim 62 (depends on 37, 38, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The Drug-Linker compound of any one of claims 37-38 or 41-61, wherein Y-D is
and
the wavy line indicates the site of attachment to the rest of the Drug-Linker compound or salt thereof.

### Claim 63 (depends on 37, 38, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The Drug-Linker compound of any one of claims 37-38 or 41-61, wherein Y-D is
and
the wavy line indicates the site of attachment to the rest of the Drug-Linker compound or salt thereof.

### Claim 64 (depends on 37, 41, 42, 45, 46, 47, 48, 52, 53, 54, 58, 59, 60, 61)

The Drug-Linker compound of any one of claims 37, 41-42, 45-48, 52-54, 58-61, or 62, wherein the compound is
or a salt thereof.

### Claim 65 (depends on 37, 41, 42, 45, 46, 47, 48, 52, 53, 54, 58, 59, 60, 61)

The Drug-Linker compound of any one of claims 37, 41-42, 45-48, 52-54, 58-61, or 63, wherein the compound is
or a salt thereof.

### Claim 66

A Ligand-Drug Conjugate compound of the formula:
L-(Q-D)p
or a pharmaceutically acceptable salt thereof, wherein
L is a Ligand Unit;
Q is a Linker Unit selected from the group consisting of:
(i) Z′-A-RL-,
(ii) Z′-A-RL-Y—,
(iii) Z′-A-S*—RL-,
(iv) Z′-A-S*—RL-Y—,
(v) Z′-A-B(S*)—RL-,
(vi) Z′-A-B(S*)—RL-Y—,
(vii) Z′-A-,
(viii) Z′-A-S*—W—,
(ix) Z′-A-B(S*)—W—,
(x) Z′-A-S*—W-RL-, and
(xi) Z′-A-B(S*)—W-RL-;
Z′ is a Stretcher Unit;
A is a bond or a Connector Unit;
B is a Parallel Connector Unit;
S* is a Partitioning Agent;
RL is a Releasable Linker;
W is a Amino Acid Unit;
Y is a Spacer Unit; and
D is a Drug Unit of Formula (I′):
wherein
Xb is —NR2—# or —N+R1R5—#, wherein the # denotes the point of attachment to Q, and Xa is
or
Xa and Xb are taken together with the carbon atom to which they are attached to form
wherein the asterisk denotes the carbon atom of Formula (I) that bears the Xa and Xb groups, and the # denotes the point of attachment to Q;
R1 and R5 are independently C1-C4 alkyl;
X is H, OH, —C(O)NRaRb, —S(O)2Ra, —S(O)—Ra —S(O)2NRaRb, —NHS(O)2Ra, or —NHC(O)Ra;
R2, R3, R4, R10, Ra, and Rb are each independently H or C1-C4 alkyl;
R6 is C1-C4 alkyl optionally substituted with OH;
R7 is H, C1-C4 alkyl optionally substituted with one or two OH moieties, or 5-6 membered heteroaryl;
E is phenyl or 5-6 membered heteroaryl;
R8, R9, and R11 are each independently H or OH;
n is 0, 1, 2, or 3;
m is 1, 2, 3, or 4;
q is 0 or 1;
p is an integer ranging from 1 to 12; and
wherein when X is H, at least two of R7, R8, R9, and R11 comprise an OH moiety.

### Claim 67 (depends on 66)

The Ligand-Drug Conjugate compound of claim 66, or a pharmaceutically acceptable salt thereof, wherein the Linker Unit Q is of formula (i), (ii), (iii), (iv), (x), or (xi).

### Claim 68 (depends on 66)

The Ligand-Drug Conjugate compound of claim 66, or a pharmaceutically acceptable salt thereof, wherein the Linker Unit Q is of formula (v), (vi), (ix), or (xi).

### Claim 69 (depends on 66)

The Ligand-Drug Conjugate compound of claim 66, or a pharmaceutically acceptable salt thereof, wherein the Linker Unit Q is of formula (viii), (ix), (x), or (xi).

### Claim 70 (depends on 66, 67, 68, 69)

The Ligand-Drug Conjugate compound of any one of claims 66-69, or a pharmaceutically acceptable salt thereof, wherein the Ligand Unit L and the Stretcher Unit Z together are
wherein
R17 is —CH2CH2(OCH2CH2)k—, —C1-C10 alkylene-, C1-C10 heteroalkylene-, —C3-C8 carbocyclo-, —O—(C1-C8 alkylene)-, -arylene-, —C1-C10 alkylene-arylene-, -arylene-C1-C10 alkylene-, —C1-C10 alkylene-(C3-C8 carbocyclo)-, —(C3-C8 carbocyclo)-C1-C10 alkylene-, —C3-C8 heterocyclo-, —C1-C10 alkylene-(C3-C8 heterocyclo)-, —(C3-C8 heterocyclo)-C1-C10 alkylene-, —C1-C10 alkylene-C(═O)—, C1-C10 heteroalkylene-C(═O)—, —C3-C8 carbocyclo-C(═O)—, —O—(C1-C8 alkylene)-C(═O)—, -arylene-C(═O)—, —C1-C10 alkylene-arylene-C(═O)—, -arylene-C1-C10 alkylene-C(═O)—, —C1-C10 alkylene-(C3-C8 carbocyclo)-C(═O)—, —(C3-C8 carbocyclo)-C1-C10 alkylene-C(═O)—, —C3-C8 heterocyclo-C(═O)—, —C1-C10 alkylene-(C3-C8 heterocyclo)-C(═O)—, —(C3-C8 heterocyclo)-C1-C10 alkylene-C(═O)—, —C1-C10 alkylene-NH—, C1-C10 heteroalkylene-NH—, —C3-C8 carbocyclo-NH—, —O—(C1-C8 alkylene)-NH—, -arylene-NH—, —C1-C10 alkylene-arylene-NH—, -arylene-C1-C10 alkylene-NH—, —C1-C10 alkylene-(C3-C8 carbocyclo)-NH—, —(C3-C8 carbocyclo)-C1-C10 alkylene-NH—, —C3-C8 heterocyclo-NH—, —C1-C10 alkylene-(C3-C8 heterocyclo)-NH—, —(C3-C8 heterocyclo)-C1-C10 alkylene-NH—, —C1-C10 alkylene-S—, C1-C10 heteroalkylene-S—, —C3-C8 carbocyclo-S—, —O—(C1-C8 alkylene)-S—, -arylene-S—, —C1-C10 alkylene-arylene-S—, -arylene-C1-C10 alkylene-S—, —C1-C10 alkylene-(C3-C8 carbocyclo)-S—, —(C3-C8 carbocyclo)-C1-C10 alkylene-S—, —C3-C8 heterocyclo-S—, —C1-C10 alkylene-(C3-C8 heterocyclo)-S—, or —(C3-C8 heterocyclo)-C1-C10 alkylene-S—;
subscript k is an integer ranging from 1 to 36;
R17 is optionally substituted by a Basic Unit (BU) such as an aminoalkyl moiety, e.g. —(CH2)xNH2, —(CH2)xNHRa, and —(CH2)xNRa2, wherein x is an integer of from 1-4 and each Ra is independently selected from the group consisting of C1-6 alkyl and C1-6 haloalkyl, or two Ra groups are combined with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl or piperidinyl group; and
the wavy line indicates the point of covalent attachment to the rest of the Ligand-Drug Conjugate compound.

### Claim 71 (depends on 66, 67, 68, 69, 70)

The Ligand-Drug Conjugate compound of any one of claims 66-70, or a pharmaceutically acceptable salt thereof, wherein the Ligand Unit L and the Stretcher Unit Z together are
wherein the wavy lines indicate the point of covalent attachment to the rest of the Ligand-Drug Conjugate compound.

### Claim 72 (depends on 66, 67, 68, 69, 70, 71)

The Ligand-Drug Conjugate compound of any one of claims 66-71, or a pharmaceutically acceptable salt thereof, wherein the Connector Unit A is
wherein
each R100 is independently selected from hydrogen or —C1-C3 alkyl;
R111 is independently selected from the group consisting of hydrogen, p-hydroxybenzyl, methyl, isopropyl, isobutyl, sec-butyl, —CH2OH, —CH(OH)CH3, —CH2CH2SCH3, —CH2CONH2, —CH2COOH, —CH2CH2CONH2, —CH2CH2COOH, —(CH2)3NHC(═NH)NH2, —(CH2)3NH2, —(CH2)3NHCOCH3, —(CH2)3NHCHO, —(CH2)4NHC(═NH)NH2, —(CH2)4NH2, —(CH2)4NHCOCH3, —(CH2)4NHCHO, —(CH2)3NHCONH2, —(CH2)4NHCONH2, —CH2CH2CH(OH)CH2NH2, 2-pyridylmethyl-, 3-pyridylmethyl-, 4-pyridylmethyl-,
each subscript c is an independently selected integer from 1 to 10; and
the wavy lines indicate attachment of the Connector Unit to the rest of the Ligand-Drug Conjugate compound or pharmaceutically acceptable salt thereof.

### Claim 73 (depends on 66, 67, 68, 69, 70, 71, 72)

The Ligand-Drug Conjugate compound of any one of claims 66-72, or a pharmaceutically acceptable salt thereof, wherein the Connector Unit A is
c is an integer ranging from 1 to 6; and
the wavy lines indicate the site of attachment to the rest of the Ligand-Drug Conjugate compound or pharmaceutically acceptable salt thereof.

### Claim 74 (depends on 66, 67, 68, 69, 70, 71)

The Ligand-Drug Conjugate compound of any one of claims 66-71, or a pharmaceutically acceptable salt thereof, wherein A is a bond.

### Claim 75 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74)

The Ligand-Drug Conjugate compound of claims 66-74, or a salt thereof, wherein B is
each AA is independently a proteinogenic or non-proteinogenic amino acid; and
the wavy lines indicate points of attachment to the rest of the Ligand-Drug Conjugate compound or pharmaceutically acceptable salt thereof.

### Claim 76 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The Ligand-Drug Conjugate compound of any one of claims 66-75, or a pharmaceutically acceptable salt thereof, wherein B is an amino acid.

### Claim 77 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The Ligand-Drug Conjugate compound of any one of claims 66-76, or a pharmaceutically acceptable salt thereof, wherein B is
the wavy line indicates the point of attachment to the Partitioning Agent S*; and
the asterisks indicate points of attachment to the rest of the Ligand-Drug Conjugate compound or pharmaceutically acceptable salt thereof.

### Claim 78 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The Ligand-Drug Conjugate compound of any one of claims 66-77, or a pharmaceutically acceptable salt thereof, wherein the Partitioning Agent S* is a polyethylene glycol (PEG) unit, cyclodextrin unit, polyamide, hydrophilic peptide, polysaccharide, or dendrimer.

### Claim 79 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The Ligand-Drug Conjugate compound of any one of claims 66-78, or a pharmaceutically acceptable salt thereof, wherein the Partitioning Agent S* is a PEG Unit comprising from 4 to 72 (CH2CH2O) subunits.

### Claim 80 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The Ligand-Drug Conjugate compound of any one of claims 66-79, or a pharmaceutically acceptable salt thereof, wherein the PEG Unit is
b is selected from the group consisting of 4 to 36; and
the wavy lines indicate the site of attachment to the rest of the Ligand-Drug Conjugate compound or pharmaceutically acceptable salt thereof.

### Claim 81 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The Ligand-Drug Conjugate compound of any one of claims 66-80, or a pharmaceutically acceptable salt thereof, wherein the Releasable Linker RL is
-(AA)1-12-; and
each AA is independently a proteinogenic or non-proteinogenic amino acid.

### Claim 82 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The Ligand-Drug Conjugate compound of any one of claims 66-81, or a pharmaceutically acceptable salt thereof, wherein the Releasable Linker RL is
-AA1-AA2- or -AA1-AA2-AA3-, wherein AA1 is attached to the Stretcher Unit Z or the Connector Unit A.

### Claim 83 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The Ligand-Drug Conjugate compound of any one of claims 66-82, or a pharmaceutically acceptable salt thereof, wherein the Releasable Linker RL is
and
the wavy line adjacent to the —NH— group indicates attachment to the Stretcher Unit Z or the Connector Unit A and the wavy line adjacent to the —C(═O)— group indicates attachment to the Spacer Unit Y or the Drug Unit D.

### Claim 84 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The Ligand-Drug Conjugate compound of any one of claims 66-83, or a pharmaceutically acceptable salt thereof, wherein the Releasable Linker RL is a glycoside.

### Claim 85 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)

The Ligand-Drug Conjugate compound of any one of claims 66-84, or a pharmaceutically acceptable salt thereof, wherein the Releasable Linker RL is
wherein
Su is a hexose form a monosaccharide;
O′ represents the oxygen atom of a glycosidic bond that is capable of cleavage by a glycosidase;
the wavy line marked with a single asterisk (*) indicates the site of covalent attachment to D; and
the wavy line marked with a double asterisk (**) indicates the site of covalent attachment to the remainder of Q.

### Claim 86 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

The Ligand-Drug Conjugate compound of any one of claims 66-85, or a pharmaceutically acceptable salt thereof, wherein the Releasable Linker RL is
the wavy line marked with a single asterisk (*) indicates the site of covalent attachment to D; and
the wavy line marked with a double asterisk (**) indicates the site of covalent attachment to the remainder of Q.

### Claim 87 (depends on 66, 67, 68, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The Ligand-Drug Conjugate compound of any one of claims 66-68 or 70-86, or a pharmaceutically acceptable salt thereof, wherein the Spacer Unit Y is
wherein EWG is an electron-withdrawing group; and
the wavy lines indicate the site of attachment to the rest of the Ligand-Drug Conjugate compound or pharmaceutically acceptable salt thereof.

### Claim 88 (depends on 66, 67, 68, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

The Ligand-Drug Conjugate compound of any one of claims 66-68 or 70-87, or a pharmaceutically acceptable salt thereof, wherein the Spacer Unit Y is
and
the wavy lines indicate the site of attachment to the rest of the Ligand-Drug Conjugate compound or pharmaceutically acceptable salt thereof.

### Claim 89 (depends on 66, 67, 70, 71, 74, 81, 82, 83)

The Ligand-Drug Conjugate compound of any one of claims 66-67, 70-71, 74, 81-83, or 87-88, or a pharmaceutically acceptable salt thereof, wherein
R17 is C1-C10 alkylene;
A is a bond;
RL is -AA1-AA2-;
AA1 and AA2 are each independently a proteinogenic amino acid;
Y is
and
the wavy lines indicate the site of attachment to the rest of the Ligand-Drug Conjugate compound or pharmaceutically acceptable salt thereof.

### Claim 90 (depends on 66, 67, 70, 71, 74, 81, 82, 83)

The Ligand-Drug Conjugate compound of any one of claims 66-67, 70-71, 74, 81-83, or 87-89, or a pharmaceutically acceptable salt thereof, wherein
A is a bond;
RL is
and
Y is

### Claim 91 (depends on 66, 67, 70, 71, 74, 81, 82, 83)

The Ligand-Drug Conjugate compound of any one of claims 66-67, 70-71, 74, 81-83, or 87-90, or a pharmaceutically acceptable salt thereof, wherein Y-D is
and
the wavy line indicates the site of attachment to the rest of the Ligand-Drug Conjugate compound or pharmaceutically acceptable salt thereof.

### Claim 92 (depends on 66, 67, 70, 71, 74, 81, 82, 83)

The Ligand-Drug Conjugate compound of any one of claims 66-67, 70-71, 74, 81-83, or 87-90, or a pharmaceutically acceptable salt thereof, wherein Y-D is
and
the wavy line indicates the site of attachment to the rest of the Ligand-Drug Conjugate compound or pharmaceutically acceptable salt thereof.

### Claim 93 (depends on 66, 67, 70, 71, 74, 81, 82, 83)

The Ligand-Drug Conjugate compound of any one of claims 66-67, 70-71, 74, 81-83, or 87-91, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 94 (depends on 66, 67, 70, 71, 74, 81, 82, 83, 87, 88, 89, 90)

The Ligand-Drug Conjugate compound of any one of claims 66-67, 70-71, 74, 81-83, 87-90, or 92, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 95 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The Ligand-Drug Conjugate compound of any one of claims 66-94, wherein p is an integer ranging from 2 to 8.

### Claim 96 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The Ligand-Drug Conjugate compound of any one of claims 66-95, wherein p is 4.

### Claim 97 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

A pharmaceutical composition comprising the Ligand-Drug Conjugate compound of any one of claims 66-94 and a pharmaceutically acceptable excipient.

### Claim 98 (depends on 97)

The pharmaceutical composition of claim 97, wherein the composition comprises a plurality of Ligand-Drug Conjugate compounds with an average drug-loading from 2 to 8.

### Claim 99 (depends on 98)

The pharmaceutical composition of claim 98, wherein the average drug loading is about 4.

### Claim 100 (depends on 98)

The pharmaceutical composition claim 98, wherein the average drug loading is from 3.5 to 4.5.

### Claim 101 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

A method of treating cancer comprising administering a therapeutically effective amount of the Ligand-Drug Conjugate compound of any one of claims 66-96, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

### Claim 102 (depends on 101)

The method of claim 101, wherein the subject tolerates treatment from the Ligand-Drug Conjugate compound better than another Ligand-Drug Conjugate compound in therapeutically effective doses.

### Claim 103 (depends on 102)

The method of claim 102, wherein the another Ligand-Drug Conjugate compound comprises a monomethyl auristatin E or monomethyl auristatin F Drug Unit.

### Claim 104

A compound, wherein the compound is selected from the group consisting of the compounds listed in Table 1 or a salt thereof.

### Claim 105

A Drug-Linker compound, wherein the Drug-Linker compound is selected from the group consisting of the compounds listed in Table 2 or a salt thereof.

### Claim 106

A Ligand-Drug Conjugate compound, wherein the Ligand-Drug Conjugate compound is selected from the group consisting of the compounds listed in Table 3, or a salt thereof, and p is an integer ranging from 1 to 12.

### Claim 107 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 106)

The Ligand-Drug Conjugate compound of any one of claims 66-96 or 106, wherein L is an antibody.

### Claim 108 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 106, 107)

The Ligand-Drug Conjugate compound of any one of claims 66-96 or 106-107, wherein L comprises an amino acid sequence that is at least 80% identical to the amino acid sequence of any one of SEQ ID Nos. 1 to 1044.

### Claim 109 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 106, 107, 108)

The Ligand Drug-Conjugate of any one of claims 66-96 or 106-108, wherein L comprises an amino acid sequence that is at least 85% identical to the amino acid sequence of any one of SEQ ID Nos. 1 to 1044.

### Claim 110 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 106, 107, 108, 109)

The Ligand Drug-Conjugate of any one of claims 66-96 or 106-109, wherein L comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of any one of SEQ ID Nos. 1 to 1044.

### Claim 111 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 106, 107, 108, 109, 110)

The Ligand Drug-Conjugate of any one of claims 66-96 or 106-110, wherein L comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of any one of SEQ ID Nos. 1 to 1044.

### Claim 112 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 106, 107, 108, 109, 110, 111)

The Ligand Drug-Conjugate of any one of claims 66-96 or 106-111, wherein L comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of any one of SEQ ID Nos. 1 to 1044.

### Claim 113 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 106, 107, 108, 109, 110, 111, 112)

The Ligand Drug-Conjugate of any one of claims 66-96 or 106-112, wherein L comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of any one of SEQ ID Nos. 1 to 1044.

### Claim 114 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 106, 107, 108, 109, 110, 111, 112, 113)

The Ligand-Drug Conjugate compound of any one of claims claim 66-96 or 106-113, wherein L comprises the amino acid sequence of any one of SEQ ID Nos. 1 to 1044.

### Claim 115 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 106, 107, 108, 109, 110, 111, 112, 113, 114)

The Ligand-Drug Conjugate compound of any one of claims 66-96 or 106-114, wherein L consists of the amino acid sequence of any one of SEQ ID Nos. 1 to 1044.

### Claim 116 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115)

The Ligand-Drug Conjugate of any one of claims 66-96 or 106-115, wherein p is 8.

### Claim 117 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115)

The Ligand-Drug Conjugate of any one of claims 66-96 or 106-115, wherein p is and integer from 1 to 8.

### Claim 118

A Ligand-Drug Conjugate of the following formula:
wherein L is an anti-gpNMB antibody,
and p is an integer from 1 to 14, or from 1 to 8, or is 8.

### Claim 119 (depends on 118)

The Ligand-Drug Conjugate of claim 118, wherein the anti-gpNMB antibody comprises an amino acid sequence that is at least 80, 85, 90, 95, 98, or 99% identical to the amino acid sequence of any one of SEQ ID Nos. 935-944.
